Jarrett Stephen, Yang Lingjiang, Pagliusi Sonia
Gracious International Inc., 28 Jiafeng Road, Shanghai 200131, China.
ChengDu Institute of Biological Products Ltd., 379 3 Section, Jinhua Road, Jinjiang District, Chengdu 610023, China.
Vaccine X. 2020 Jun 9;5:100068. doi: 10.1016/j.jvacx.2020.100068. eCollection 2020 Aug 7.
Manufacturers have a significant stake in the vaccine supply chain as their reputations rest on the effectiveness of their vaccines at the point of vaccination. The risks of low performing supply chains are detrimental for the safety and effectiveness of vaccines, with potential consequences to future supply in the case of adverse events. For this reason, a study was set up to explore the involvement of developing country manufacturers in the vaccine supply chain over the next decade to determine the areas where innovations could have a positive impact on the supply chain, focusing on the secondary stages of production where formulation, filling and packaging take place. An expert desk review identified eight areas of interest for the vaccine supply chain and informed the development of a survey to assess the relevance of the areas identified. The review also conjectured whether the overall effect of the identified areas is cost-neutral or resulting in net savings to countries. Overall, respondents identified five areas as of highest interest and subsequently an expert working group of representative manufacturers prioritized three of them. Specifically, traceability in the context of global digital health initiatives, stockpiling in the context of addressing vaccine shortages, stock-outs, outbreaks and epidemic prevention, and new packaging technologies are discussed in this report. It is important that vaccine manufacturers be actively engaged in global stakeholders' forums, as equal partners in determining the best ways for improving the vaccine supply chain.
制造商在疫苗供应链中有着重大利害关系，因为他们的声誉取决于其疫苗在接种点的有效性。表现不佳的供应链风险对疫苗的安全性和有效性有害，若发生不良事件，可能会对未来供应产生影响。因此，开展了一项研究，以探讨发展中国家制造商在未来十年参与疫苗供应链的情况，确定创新可能对供应链产生积极影响的领域，重点关注进行配方、灌装和包装的生产第二阶段。一项专家案头审查确定了疫苗供应链的八个感兴趣领域，并为开展一项调查提供了依据，以评估所确定领域的相关性。该审查还推测所确定领域的总体影响对各国而言是成本中性还是能带来净节约。总体而言，受访者确定了五个最感兴趣的领域，随后一个由代表性制造商组成的专家工作组对其中三个领域进行了优先排序。本报告具体讨论了全球数字健康倡议背景下的可追溯性、应对疫苗短缺、缺货、疫情和防疫背景下的库存储备以及新包装技术。疫苗制造商作为平等伙伴积极参与全球利益相关者论坛，对于确定改善疫苗供应链的最佳方式至关重要。
